Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.32 0.1099 +52.31%
CYTK $12.99 1.0699 +8.98%
ARRY $4.09 0.2900 +7.63%
IMNP $4.10 0.1400 +3.54%
VRML $3.00 0.1000 +3.45%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

AGIO $43.58 -2.7600 -5.96%
MEIP $8.58 -0.4900 -5.40%
OMED $25.96 -1.2200 -4.49%
CVM $1.22 -0.0500 -3.94%
MDVN $57.72 -2.3200 -3.86%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Stress Can Sabotage Effectiveness of Cancer Drugs

(Los Angeles Times) Sept 22, 2010 - Is there no end to the ways that stress can kill us? Scientists now believe that physical or psychological stress just before cancer therapy might sabotage the helpful drugs.
read article (free registration required) 

A Huge Day For Cancer Patients

(Forbes Blog) Sept 23, 2010 - On any given day, there are ten million people in the United States who are battling some form of cancer. It is a war that is neither pretty nor cheap.
read article 

Insurers Scramble to Comply With New Rules

(New York Times) Sept 22, 2010 - The first big wave of new rules under the federal health care law goes into effect on Thursday, leaving many insurers scrambling to get ahead of the changes.
read article (free registration required) 

Sanofi-Aventis: Signs Cancer Partnership With Belfer Institute

(DowJones/NASDAQ) Sept 23, 2010 - French pharmaceutical company Sanofi-Aventis S.A. said Thursday it has signed a partnership pact with the Belfer Institute of Applied Cancer Science in Boston, Massachusetts, to develop new cancer treatments.
read article 

FDA Restricts Glaxo Diabetes Drug Avandia

(TheStreet) Sept 23, 2010 - The U.S. Food and Drug Administration announced on Thursday that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone), manufactured by GlaxoSmithKline(GSK_), to patients with Type 2 diabetes who cannot control their diabetes on other medications.
read article 

FDA: Sees Possible Risk Of Bowel Problem With Glaxo's Rotarix

(Dow Jones/MorningStar)Sept 22, 2010 - The Food and Drug Administration said preliminary results from a study in Mexico involving GlaxoSmithKline PLC's (GSK, GSK.LN) Rotarix vaccine suggest an increased risk of a serious bowel problem.
read article 

New UF Study Examines Patient Treatment Decisions for Colorectal Cancer

(Univ. of Florida Gainesville) Sept 23, 2010 - A new University of Florida study will take an in-depth look at the factors involved in treatment decisions made by people with colorectal cancer.
read press release 

Novo Says Cancer Risk with Insulin Drops Over Time

(Reuters) Sept 23, 2010 - The raised risk of cancer in people using insulin decreases over time, a large study showed, Novo Nordisk, the world's biggest maker of insulin, said on Thursday.
read article 

Experimental Leukemia Drug Proves a Slam Dunk

(U.S. News & World Report) Sept 23, 2010 - It was August 2004, and 24-year-old Ray Johnston was living his boyhood dream.
read article 

Biothera Receives National Cancer Institute Award for Pancreatic Cancer Study

(Yahoo! Finance) Sept 23, 2010 - Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG® in pancreatic cancer, the company announced today.
read article 

Amgen Eyes Deals, International Expansion

(Reuters) Sept 22, 2010 - Amgen Inc is aggressively eyeing global expansion and looking at acquisition opportunities and drug licensing deals that can help the world's largest biotechnology company to achieve that goal.
read article 

Expert Answers About Melanoma

(NYT Consults Blog) Sept 20, 2010 - Dr. David E. Fisher of Harvard Medical School addresses readers concerns about aging skin and the risk of melanoma, recurrences of the deadly skin cancer and melanoma that has spread to the nasal cavity.
read article (free registration required) 

Lance Armstrong Addresses World's Cancer Crisis at Clinton Global Initiative Annual Meeting

(MSNBC) Sept 22, 2010 - Today, Lance Armstrong, LIVESTRONG® founder and chairman, cancer survivor and champion cyclist, addressed the growing international cancer crisis at the Clinton Global Initiative (CGI) Annual Meeting in New York City.
read article 

Study: Broader Telephone-Based Health Coaching May Save Money

(WSJ Health Blog) Sept 23, 2010 - Offering telephone health coaching to a broader-than-usual swath of patients may save money, according to a study just published in the New England Journal of Medicine.
read article (paid subscription required) 

Soon, Nose Drops to Treat Brain Cancer

(The Times of India) Sept 23, 2010 - Scientists have reported the development and testing of a drug that could treat brain cancer, and can be given as nose drops rather than an injection.
read article 

NCCN Announces New Treatment Guidelines for Patients

(NCCN) Sept 23, 2010 - The National Comprehensive Cancer Network® (NCCN®) announces the NCCN Guidelines for Patients™, a new tool to empower patients with cancer and their caregivers to take a more active role in their treatment.
download pdf 

Yale Hockey Player Has Stem-Cell Transplant

(New York Times) Sept 23, 2010 - Mandi Schwartz, the Yale hockey player whose battle with leukemia has drawn widespread attention, underwent a stem-cell transplant on Wednesday that her doctors hope will save her life.
read article (free registration required) 

Vermillion Appoints Jeffrey M. Salzman as Corporate Director of Reimbursement

(BizJournal) Sept 23, 2010 - Vermillion, Inc., a molecular diagnostics company, today announced the appointment of Jeffrey M. Salzman as Corporate Director of Reimbursement. In his role, Mr. Salzman will be responsible for developing and executing payor strategies for Vermillion.
read article 

AstraZeneca Cancer Drug Gets Fast-Track FDA Review

(DowJones/SmartMoney) Sept 23, 2010 - An experimental AstraZeneca PLC pill called vandetanib has been filed for approval in the U.S. and Europe after data showed the drug delayed progression of a rare type of thyroid cancer, and U.S. regulators have given the medicine a priority review.
read article 

ZIOPHARM Receives FDA Orphan Drug Designation for Darinaparsin in the Treatment of Peripheral T-cell Lymphoma

(StreetInsider) Sept 23, 2010 - ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL).
read article 

Mammogram Benefits More Modest Than Doctors Thought

(USA Today) Sept 23, 2010 - Nearly one year after the publication of controversial breast cancer screening guidelines by a government-appointed expert panel, a new study suggests benefits of mammograms may be more modest than previously estimated.
read article 

FDA Approves First MS Treatment in Pill Form

(CNNHealth Blog) Sept 22, 2010 - The Food and Drug Administration (FDA) has approved the first oral drug for treating relapsing-remitting multiple sclerosis (MS), the most common form of the disease.
read article 

Novartis Cushing's Drug Passes Late-Stage Test

(TheStreet) Sept 22, 2010 - Novartis it will seek regulatory approval by the end of the year for a new drug to treat Cushing's disease based on positive results from a phase III study released Wednesday.
read article 

Sanofi-Aventis Says Tamaris Phase III Trial Did Not Mean Primary Endpoint

(Bloomberg) Sept 22, 2010 - Sanofi-Aventis SA said a drug that had showed promise in restoring blood vessel growth in damaged limbs was no better than a placebo in an advanced test.
read article 

Staying on Gleevec Seems to Help Gastro Cancer Patients

(Bloomberg Businessweek) Sept 22, 2010 - Continuous treatment with imatinib (Gleevec) is recommended for patients with advanced gastrointestinal cancer, a new study suggests.
read article